Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extensionJeffrey S. Hyams, Robert N. Baldassano, George D. Ferry et al.|Current Medical Research and Opinion|2011Cited by 109